1. Home
  2. OPT

as 12-11-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.

Founded: 1984 Country:
Australia
Australia
Employees: N/A City: N/A
Market Cap: 767.9M IPO Year: 2020
Target Price: $12.00 AVG Volume (30 days): 27.6K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.35 EPS Growth: N/A
52 Week Low/High: $1.79 - $5.45 Next Earning Date: 08-30-2024
Revenue: $261,859 Revenue Growth: -32.03%
Revenue Growth (this year): -32.5% Revenue Growth (next year): 46864.64%

OPT Daily Stock ML Predictions

Share on Social Networks: